暖心胶囊治疗慢性充血性心力衰竭的临床研究
|
摘要
目的:
观察暖心胶囊对慢性收缩性心力衰竭临床疗效的影响。
方法:
选择慢性充血性心力衰竭患者100例随机分为治疗组与对照组,对照组50例予西医基础治疗,治疗组50例在西医基础治疗上同时服用暖心胶囊,3粒/次,3次/天,疗程6个月。观察两组治疗前后的主要指标疗效、中医症状积分改善情况及6分钟步行距离,评价再次住院率,检测治疗前后心功能参数及血浆脑钠肽(BNP)的含量等。
结果:
1.治疗组与对照组均能改善心衰患者主要指标疗效,两组比较,治疗组明显高于对照组(P<0.05);
2.两组均能改善气促、四肢浮肿、心悸、疲倦乏力、自汗、胸闷、头晕、尿少、畏寒肢冷、腹胀等症状积分,但治疗组较优(P<0.05);治疗组在改善患者纳呆、气短、口唇紫暗、面色苍白、舌淡胖、舌质暗、脉弱无力、脉结或代等症状积分方面,治疗前后及与对照组比较均有显著性差异(P<0.05),对照组治疗前后无统计学差异(P>0.05);
3.治疗组再次住院率低于对照组,两组有显著性差异(P<0.05);
4.两组均能改善左心收缩功能、舒张功能相关指标,暖心胶囊组较对照组改善左心收缩、舒张功能更为明显,两组差异有显著性(P<0.05);
5.两组均能使心衰患者6分钟步行距离提高,暖心胶囊组较对照组提高更优,有显著性差异(P<0.05);
6.两组均能使心衰患者BNP水平降低,暖心胶囊组较对照组降低更著,两组具有显著性差异(P<0.05)。
结论:
暖心胶囊是临床疗效好的药物。暖心胶囊对于心力衰竭患者有确切疗效,能够改善心衰患者症状、降低心衰患者再次住院率、提高患者的6分钟步行距离和可能对降低病死率有益等较好疗效,且未发生毒、副作用。此外暖心胶囊对左心收缩、舒张功能的改善较优;降低BNP作用更著,从另一个角度提示暖心胶囊对心衰程度缓解可能对长期预后有益。其可能作用机理是作用于心衰的多个环节、多个靶点,确切机理尚需进一步研究。进一步积累该药循证医学依据,将为延缓心衰进程、降低心衰病死率的研究提供新视角。
Objective:This study was performed to observe the curative effect of the traditional Chinese herb medicine Nuanxin Capsule on the disease of chronic congestive heart failure. Methods:①100 patients with CHF were divided randomly into two groups: the controlled group (treated with appropriate western medicine for CHF)and the treatment group (treated with Nuanxin Capsule as well as the same kinds of western medicine as given to the controlled group), there were 50 patients in each group.The dosage for Nuanxin Capsule was 3 capsules, 3 times daily. The treatment time was six months;②Observing the symptoms, signs and total effective ratios before and after the treatment, making a statistical disposal and comparing the curative effect;③Examining six-minute walking test, ultrasonic cardiogranu BNP in the blood et al before and after the treatment and analyzing the rehospitalization rate. Results:①The symptoms and signs of the patients on the two groups after the treatment were better than those before treatment. Compared between the two groups, the total effective rate of the treatment group was significantly better than the controlled group(P <0. 05).②As compared with the controlled group, the rate of rehospitalization in the treatment group after treatment was significantly low (P<0.05).③The parameters of the left ventricular systolic and diastolic function
观察暖心胶囊对慢性收缩性心力衰竭临床疗效的影响。
方法:
选择慢性充血性心力衰竭患者100例随机分为治疗组与对照组,对照组50例予西医基础治疗,治疗组50例在西医基础治疗上同时服用暖心胶囊,3粒/次,3次/天,疗程6个月。观察两组治疗前后的主要指标疗效、中医症状积分改善情况及6分钟步行距离,评价再次住院率,检测治疗前后心功能参数及血浆脑钠肽(BNP)的含量等。
结果:
1.治疗组与对照组均能改善心衰患者主要指标疗效,两组比较,治疗组明显高于对照组(P<0.05);
2.两组均能改善气促、四肢浮肿、心悸、疲倦乏力、自汗、胸闷、头晕、尿少、畏寒肢冷、腹胀等症状积分,但治疗组较优(P<0.05);治疗组在改善患者纳呆、气短、口唇紫暗、面色苍白、舌淡胖、舌质暗、脉弱无力、脉结或代等症状积分方面,治疗前后及与对照组比较均有显著性差异(P<0.05),对照组治疗前后无统计学差异(P>0.05);
3.治疗组再次住院率低于对照组,两组有显著性差异(P<0.05);
4.两组均能改善左心收缩功能、舒张功能相关指标,暖心胶囊组较对照组改善左心收缩、舒张功能更为明显,两组差异有显著性(P<0.05);
5.两组均能使心衰患者6分钟步行距离提高,暖心胶囊组较对照组提高更优,有显著性差异(P<0.05);
6.两组均能使心衰患者BNP水平降低,暖心胶囊组较对照组降低更著,两组具有显著性差异(P<0.05)。
结论:
暖心胶囊是临床疗效好的药物。暖心胶囊对于心力衰竭患者有确切疗效,能够改善心衰患者症状、降低心衰患者再次住院率、提高患者的6分钟步行距离和可能对降低病死率有益等较好疗效,且未发生毒、副作用。此外暖心胶囊对左心收缩、舒张功能的改善较优;降低BNP作用更著,从另一个角度提示暖心胶囊对心衰程度缓解可能对长期预后有益。其可能作用机理是作用于心衰的多个环节、多个靶点,确切机理尚需进一步研究。进一步积累该药循证医学依据,将为延缓心衰进程、降低心衰病死率的研究提供新视角。
Objective:This study was performed to observe the curative effect of the traditional Chinese herb medicine Nuanxin Capsule on the disease of chronic congestive heart failure. Methods:①100 patients with CHF were divided randomly into two groups: the controlled group (treated with appropriate western medicine for CHF)and the treatment group (treated with Nuanxin Capsule as well as the same kinds of western medicine as given to the controlled group), there were 50 patients in each group.The dosage for Nuanxin Capsule was 3 capsules, 3 times daily. The treatment time was six months;②Observing the symptoms, signs and total effective ratios before and after the treatment, making a statistical disposal and comparing the curative effect;③Examining six-minute walking test, ultrasonic cardiogranu BNP in the blood et al before and after the treatment and analyzing the rehospitalization rate. Results:①The symptoms and signs of the patients on the two groups after the treatment were better than those before treatment. Compared between the two groups, the total effective rate of the treatment group was significantly better than the controlled group(P <0. 05).②As compared with the controlled group, the rate of rehospitalization in the treatment group after treatment was significantly low (P<0.05).③The parameters of the left ventricular systolic and diastolic function
引文
[1] Cowie MR, Mosterd A, Wood DA, et. The epidemiology of heart failure. Eur Heart J, 1999; 18: 208-225.
[2] Cleland JGF. Improving patient outcomes in heart failure: Evidence and barriers. Heart, 2000; 84(Suppl Ⅰ): 8-10.
[3] American Heart Association. 2002 Heart and stroke statistical update. American Heart Association, Dallas(Tex) 2001.
[4] 顾东风,黄广勇,何江,等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志,2003;31(1):3-6.
[5] 中华医学会心血管病学分会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查.中华心血管病杂志,2002;30(8):450-454。
[6] Kannel WB. Vital epidemiology clues in heart failure. J Clin Epidemiol, 2000;53:229-235.
[7] Foody J M, Farrel M H, Krumholz H M. Beta blocker therapy in heart failure: scientific review[J]. JAMA, 2002;287(7): 883-889.
[8] Komajda M, Wimart MC. Angiotensin converting enzyme inhibition: From viper to patient. Heart, 2000; 84(Suppl Ⅰ): 11-14.
[9] 葛丽华,刘梅林.发展中国家心衰人群的流行病学特点.中华实用医药杂志,2003;3(17):1576-1578.
[10] 郑三晖,庄霖鹏,曾哲.766例住院慢性心衰患者病因分析.河北医学,2004;10(2):130-132.
[11] 薛礼美,陈晓虎,汤粉英,等.CHF的神经内分泌激素、细胞因子变化的研究进展.医学综述,2004;10(3):146-150.
[12] Globits S, Frank H, Packer B, et al. Atrail natriuretic Peptide release is more dependent on atrial filling volume than on filling pressure in chronic CHF[J]. Am Heart J, 1998; 135(4): 592-597.
[13] 钱方毅.重视心力衰竭发病中的神经内分泌细胞因子系统的研究.中国循环杂志,2001;16(4):243.
[14] Danser AH, Vankesteren CA, Bax WA, et al. Prorenin, venin, angiotensin and angiotensin—converting enzyme in normal and failing human hearts[J]. Circulation, 1997; 96(1): 220-226.
[15] Yoshimura M, Yasue H, Ogawa H. PathoPhysiological significance and clinical application of ANP and BNP in patients with heart failure[J]. Can J Physiol Pharmacol, 2001; 79: 730-735.
[16] 陶则伟,黄元伟.心衰学说的发展与防治.心血管病学进展,2003;24(1):67-70.
[17] Sutton M G J, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy[J]. Circulation, 2000; 101(22): 2981—2988.
[18] 陈齐红,覃数.肿瘤坏死因子—α和充血性心力衰竭.心血管病学进展,2004;25(2):89-91.
[19] Nicheretr J, Kemp M, Donrignez M, et al. Acute peripheral edetna in patients with chronic heart failure isessociate with endotoxemia and immune activation. J Am Coll Cardiol, 1998; 31: 155.
[20] Niebauer J, Colk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999; 353: 1838-42.
[21] Mckinney W. Bacterial lipopolyoaccharide-atimulated releases of tumor necrosis factor-alpha from the isolated rat heart: the effect of aprotinin and forekolin[J]. Am Surg, 2003; 69: 131-135.
[22] Levine B, KaLman, Mayer L, et al. Elevated circulation levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990; 323(4): 236-241.
[23] 邱飞,王礼琛.肿瘤坏死因子α与心力衰竭的研究进展.国外医学药学分册,2003;30(6):326-330.
[24] Loppnow H, Westphal E, Buchhorn R, et al. Interleukin—1 and related protein in cardiovascular disease in adults and children. Shock, 2001; 16: 3—9.
[25] Torre—Amion G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction(SOLVD)[J]. J Am Coll Cardiol, 1996; 27: 1202-1206.
[26] Berton C, Cordiano R. C-reactive Protein in acute myocardial infarction: association with heart failure [J]. Am Heart J, 2003; Jun, 145(6): 1094-101.
[27] Alonso-Martinez JL, Elorent-Diez B. C-reactive protein as predictor of improvement and readmission in heart failure[5]. Eur J Heart Fail, 2002; 4(3): 331-336.
[28] 励伟芬,柳茵,钟良.充血性心力衰竭患者血浆C反应蛋白水平变化及其意义.心脑血管病防治,2004;4(1):30-32.
[29] 尹芝兰,赵水平.充血性心力衰竭患者血清C-反应蛋白的变化及辛伐他汀的干预 作用.中国医师杂志,2003:5(9):1225-1226.
[30] 孙宁玲,李明.慢性充血性心力衰竭患者血浆中C-反应蛋白、肾上髓质素及内皮素水平变化的研究.中国循环杂志,2000;15(1):37-39.
[31] 金伟东,陶以嘉,潘宇红.纤维蛋白原,C-反应蛋白,白细胞计数与心功能不全的关系.中国临床医学,2001;8(3):259-260.
[32] Aukrust P, UelandT, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. AM J Cardiol, 1999; 83: 376-382.
[33] Takahashi N, Seko Y, Azuma M, et al. Evidence of cell-mediated cardiac myocyte injury involved in the heart failure of a patient with progressive systemic sclerosis[J]. Jpn Circ J, 1999; 63(1): 68-72.
[34] 陶志刚,于凌云,王洪敏.慢性充血性心力衰竭患者血清可溶性细胞问粘附分子-1的变化及与C-反应蛋白的相关性分析.中国心血管病研究杂志,2004,2(1):31-33.
[35] Lee RT, Lammerding J. Signaling pathways that influence extracellular remodeling. J Card Fail, 2002;8(6 Suppl):339-43.
[36] 陈晓锋,顾振纶,唐礼江.基质金属蛋白酶在心衰中作用的研究进展.中国药理学通报,2004;20(2):137-140.
[37] 杨志宏,郑兴.心室重构及心衰时基质金属蛋白酶的活性变化.国外医学·生理、病理科学与临床分册,2002;22(5):522-524.
[38] Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF—alpha. Int J Cardiol, 2002; 83(1): 73.
[39] 汪晓云,廖昆灵,卢微.瘦素、细胞因子与心功能不全关系的研究.贵州医药,2004;28(3):258-259.
[40] 张金国,杨娜,王学忠.充血性心力衰竭患者血浆瘦素水平的变化及其临床意义.济宁医学院学报,2003;26(4):4-6.
[41] 张子彬,Tsung O.Cheng[美],张玉传.充血性心力衰竭学.北京:科学技术文献出版社,2002年,第1版:223.
[42] The Task Force on Heart Failure of the European Society of Cardiology. Guideline for the diagnosis and treatment of chronic heart failure. Eur Heart J, 2000; 25:1527-1560.
[43] National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. London: NICE, 2003.
[44] The Digitalis investigation Group. the effect of digoxin on mortality and morbidity in patients with heart failure[J]. New Eng J Med. 1997,336: 525-533.
[45] 袁进,唐镜波.地高辛治疗充血性心衰的研究进展及再评价.药物流行病学杂志,1998;7(3):135-139.
[46] Packer M, Cohn JN. Consensus recommendation for the management of chronic heart failure[J]. Am J Cardiol, 1999; 83,1A-38A.
[47] 林曙光,陈鲁原.心力衰竭治疗领域之用药进展.中国处方药,2004;22:26-28.
[48] Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus Elderly Study ELITE. Lancet, 1997; 349:747-752.
[49] Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with heart failure: Randomized trial -The Losartan Heart failure Survival Study ELITE Ⅱ. Lancet, 2000; 355; 1582-1587.
[50] 中华医学会心血管学会.中华心血管病杂志编辑委员会.慢性收缩性心力衰竭治疗建议.中华心血管病杂志,2002;30:7-23.
[51] Philip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003; 362: 7-13.
[52] Pitt B, Zannad F, Remme WJ, et al. Spirono lactone appears benificial regardles of ejection fraction: the RALES trial[J]. Circulation, 1999; 100(Suppl): 709-717.
[53] Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation, 2001;104(4), 467-472.
[54] John A, Joseph MD, Phil MS, et al. Expanding the outcomes in clinical trials of heart failure: The quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal efficacy and survival study).Am Heart J, 2002; 143:636-42.
[55] 胡大一,马长生.心脏病学实践2002——规范化治疗,北京:人民卫生出版社,2002年,第1版:341.
[56] 李明龙.Nesiritide:一种有前途的治疗心力衰竭新药.医学综述,2004;10(1):24-26.
[57] Elkayam U, Silver MA, Burger AJ, et al. Effect of short—term therapy with nesiritide (B—type natriuretic peptide) or dobutamine on long term survival[J]. J Card Fail, 2000;6(1): 45.
[58] FarquharsonCA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation, 2002;106(2): 221-6.
[59] 杨立宪,李桂平,钟思干,等.联合用小剂量甲状腺素治疗CHF对血清甲状腺素及心功能的影响.中华现代临床医学杂志,2003;6(1):494-495.
[60] 刘海宁,张兴华,耿庆信.老年慢性充血性心力衰竭患者甲状腺激素水平及小剂量甲状腺素治疗临床观察.中华老年医学杂志,2003;22(11):656-658.
[61] 王立志,孔祥泉,王英丽,等.小剂量甲状腺素长期治疗充血性心力衰竭的临床研究.中国综合临床,2003;19(11):987-988.
[62] Frishman WH. Recent advances in cardiovascular pharmacology[J]. Curr Prob Cardio, 2000; 25(4): 225.
[63] Milton P, Robert M, et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. Circulation, 2002; 106:920.
[64] 许项立,江荣炎.慢性心力衰竭的治疗进展.第六届岭南心血管病学术会议资料汇编,广州,2004年3月,116-118.
[65] Ruschitzka F, Moehrlen U, Quaschning T, et al. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease[J].Circulation, 2000; 102(10): 1086-1092.
[66] 吴沃栋.心力衰竭生物学治疗的研究进展.广东医学,2004;25(3):343-344.
[67] Toussaint JF, Lavergne T, Olitrant J, et al. Biventricular pacing in severe heart failure patients reverses electromechanical dysynchronization from apex to base[J].PACE, 2000; 23: 1731-1734.
[68] Auricchio A, Stellbrink C, Sack S. The pacing therapies for congestive heart failure(PATH—CHF)study: rational, design and endpoints of a prospective randomized study[J]. Am J Cardial, 1999; 83: 130-135.
[69] Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: result from the multisided Stimulation in Cardiomyopathy (MUSTIC) study [J]. J Am Coll Cardiol, 2002;40(1): 111-118.
[70] Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure[J].N Engl J Med, 2002; 346: 1845-1853.
[71] 张子彬.充血性心力衰竭,北京:科学技术文献出版社,1997,第2版:576.
[72] 郭毅.试论心衰及其治疗体会.四川中医,1996;14(8):6.
[73] 曹贵民.中医对心力衰竭的认识和治疗.陕西中医学院学报,1997;20(3):6.
[74] 陈可冀.心脑血管疾病研究(M),上海:科学技术出版社,1988年,第1版:24.
[75] 张志勇,王桂平.益气活血汤治疗缺血性心肌病心力衰竭65例观察.北京中医 2000;19(2):39.
[76] 刘宗莲,徐淑文,陈鼎棋.治疗心力衰竭经验.中医杂志,2000;41(4):204.
[77] 曹雪滨,浦斌红,胡元会,等.充血性心力衰竭的中医辨证分型特点.甘肃中医学院学报,1999;16(3):13.
[78] 周仲瑛,金妙文,吴勉华,等.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究.南京中医药大学学报,2000;11(1):13-15.
[79] 毛春燕.中医对充血性心力衰竭的认识及治疗对策.河北中医,2002;24(11):823.
[80] 吴勉华.充血性心力衰竭中医病机探讨.南京中医药大学学报,2001;17(4):206.
[81] 蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况.河北中医药学报,2000;15(3):41-43.
[82] 杜惠芳,杨加禄,郭素英.慢性心衰与痰之关系初探.河南中医药学刊,1998;9(3):34-36.
[83] 冯国标.略论慢性心衰的辨证论治.河南中医药学刊,1998;13(2):6-7.
[84] 杨培君,杨磊.充血性心力衰竭的中医证治概要.陕西中医学院学报,2002;25(1):2.
[85] 谢乐.中医分型治疗充血性心力衰竭77例.四川中医,2002;20(6):41.
[86] 王素琴.心衰的中医辨证施治.河北医学,2002;8(3):283-284.
[87] 马术明.慢性充血性心力衰竭的辨证论治.吉林中医药,2004;24(2):6-8.
[88] 郑友祥,黄平,夏建华.中西医结合疗法治疗慢性充血性心力衰竭84例.现代中西医结合杂志,2004;13(5):590-591.
[89] 吕凯.健脾利水法治疗慢性心衰38例.中医研究,2002;15(2):28-29.
[90] 谭旭宏.健脾法与小剂量肝素合用在顽固性心力衰竭中的应用初探.贵阳中医学院学报,2004;26(1):29-30.
[91] 张振琪.益气活血法治疗慢性心力衰竭30例临床观察.中国医药学报,2003;18(11):702.
[92] 郭志华,毛以林,石青,等.益气活血利水法治疗慢性心力衰竭的临床研究.中华实用中西医杂志,2004;4(3):318-319.
[93] 鲁桂芬.益气温阳利水法治疗充血性心力衰竭58例.河北中医,2004;26(2):99-100.
[94] 孙长春,顾月星,王一新,等.补阳还五胶囊治疗无症状性心力衰竭48例临床观察.江苏中医药,2003;24(12):16-17.
[95] 林萍.不长稳心颗粒对老年冠心病充血性心力衰竭患者校正QT离散度的影响.中华中西医学杂志,2004;2(1):60-61.
[96] 陈志强,洪涛,赖颢,等.参附注射液治疗二尖瓣替换术后心功能不全的临床观察.中国中医急症,2003;12(6):531,561.
[97] 王燕.参附注射液治疗心功能不全疗效观察.中华中西医杂志,2003: 4(10):1533-1534.
[98] 季文.参附注射液治疗肺源性心脏病心力衰竭的临床观察.山西医药杂志,2004;33(1):79-80.
[99] 胡元会,曹雪滨,曹贵民.中药心复康治疗气虚血瘀型充血性心力衰竭33例疗效观察.浙江中医学院学报,2002;24(2):39.
[100] 吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究.山东中医杂志,2001;20(12):715.
[101] 卢健棋.参麦注射液治疗充血性心力衰竭的研究概况.中西医结合心脑血管病杂志,2003;1(10):600-601.
[102] 黄然.参麦注射液辅助治疗心力衰竭52例疗效观察.中华新医学,2004;5(2):103-104.
[103] 龙明智,王迪斌,杨季明,等.参麦注射液治疗充血性心力衰竭的临床观察.中国中西医结合杂志,2003;23(11):808-810.
[104] 陈海燕,吴焕林.参麦注射液治疗慢性充血性心力衰竭的疗效观察.现代中西医结合杂志,2004;13(1):30-31.
[105] 杨茂平,刘兴邦.生脉注射液辅助治疗难治性心力衰竭22例临床观察.中华现代中西医杂志,2003;1(5):418.
[106] 汤应宗.生脉注射液治疗顽固性心衰32例临床观察.中华医药学杂志,2003;2(10):88-89.
[107] 杨瑞华,张瑞海,孙亚利.生脉注射液治疗充血性心力衰竭30例.中国民间疗法,2004;12(1):45-46.
[108] 姜淑琴.生脉注射液治疗充血性心力衰竭的疗效观察.中华综合医学杂志,2004;6(3):64-65.
[109] 谭辉,宋开兰,刘娅.大黄对重度充血性心力衰竭患者细胞因子及氧化应激的影响.中国现代医学杂志,2003;13(22):99-100,102.
[110] 姜寅光,李隽.益母草化血中之水治慢性左心衰竭.中医杂志,2003:44(12):891.
[111] 杨孟考.单味葶苈子治疗顽固性心衰23例.中国社区医师,2002;18(20):40.
[112] 郭卫宾.灯盏花注射液治疗肺心病心衰56例疗效观察.医学文选,2003;22(6):901.
[113] 杜秀玉.红花注射液治疗肺心病顽固性心力衰竭的疗效观察.中国中西医结合杂志,2003;23(5):393.
[114] 梁春才.黄芪治疗难治性心衰近况.辽宁中医杂志,2001;28(9):575-576.
[115] 尹乐安.黄芪注射液对肺心病心力衰竭心功能的影响(附102例报告).中国医师杂志,2004;6(3):427.
[116] 刘永新.黄芪注射液联用心先安治疗肺心病心衰50例疗效分析.中国全科医 学,2003;6(11):917.
[117] 刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响.中国中西医结合杂志,2003;23(5):351-353.
[118] 翟世民.黄芪注射液辅助治疗顽固性心力衰竭的疗效观察.中国社区医师,2004;(3):33.
[119] 赵海洋,孙西武.黄芪注射液联合欣康注射液治疗心力衰竭54例临床观察.中华医学研究杂志,2003;3(5):455.
[120] 钱海凌,黄立武.大剂量黄芪注射液治疗难治性心衰的临床观察.辽宁中医杂志,2000;27(5):202-203.
[121] 唐志新,李毅夫,洪新枝,等.黄芪治疗心力衰竭及其对肿瘤坏死因子的影响.中国药房,2001;12(2):917.
[122] 邓铁涛.邓铁涛临床经验辑要,北京:中国医药科技出版社,1998年,第1版:22.
[123] 郑筱萸.中药新药临床研究指导原则(试行),北京:中国医药科技出版社,2002年,第1版:77.
[124] 郑筱萸.中药新药临床研究指导原则(试行),北京:中国医药科技出版社,2002年,第1版:378.
[125] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版:383.
[126] 邓铁涛.邓铁涛医集,北京:人民卫生出版社,1995年,第1版.
[127] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版:81.
[128] 刘宏伟,付红莉.6分钟步行试验对慢性心衰患者心功能的评估.国外医学.心血管疾病分册,2001;28(2):87-88.
[129] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版.
[130] 中华医学会心血管病学会,中华心血管病杂志编辑委员会.慢性收缩性心力衰竭治疗建议.中华心血管病杂志,2002年;30(1):7-21.
[131] Bittner V, Weiner DH, Yuauf S, et al. Prediction of niortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction [J], JAMA, 1993; 270(14): 1702-1707.
[132] 阎伟,余静.六分钟步行试验:评估慢性心衰患者心功能的一种简单客观方法.心血管病学进展.2002;23(2):86-88.
[133] Cohn JN. Structural change incardiovascular disease. Am Cardiol, 1995; 76:34.
[134] Tmughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure
[2] Cleland JGF. Improving patient outcomes in heart failure: Evidence and barriers. Heart, 2000; 84(Suppl Ⅰ): 8-10.
[3] American Heart Association. 2002 Heart and stroke statistical update. American Heart Association, Dallas(Tex) 2001.
[4] 顾东风,黄广勇,何江,等.中国心力衰竭流行病学调查及其患病率.中华心血管病杂志,2003;31(1):3-6.
[5] 中华医学会心血管病学分会.中国部分地区1980、1990、2000年慢性心力衰竭住院病例回顾性调查.中华心血管病杂志,2002;30(8):450-454。
[6] Kannel WB. Vital epidemiology clues in heart failure. J Clin Epidemiol, 2000;53:229-235.
[7] Foody J M, Farrel M H, Krumholz H M. Beta blocker therapy in heart failure: scientific review[J]. JAMA, 2002;287(7): 883-889.
[8] Komajda M, Wimart MC. Angiotensin converting enzyme inhibition: From viper to patient. Heart, 2000; 84(Suppl Ⅰ): 11-14.
[9] 葛丽华,刘梅林.发展中国家心衰人群的流行病学特点.中华实用医药杂志,2003;3(17):1576-1578.
[10] 郑三晖,庄霖鹏,曾哲.766例住院慢性心衰患者病因分析.河北医学,2004;10(2):130-132.
[11] 薛礼美,陈晓虎,汤粉英,等.CHF的神经内分泌激素、细胞因子变化的研究进展.医学综述,2004;10(3):146-150.
[12] Globits S, Frank H, Packer B, et al. Atrail natriuretic Peptide release is more dependent on atrial filling volume than on filling pressure in chronic CHF[J]. Am Heart J, 1998; 135(4): 592-597.
[13] 钱方毅.重视心力衰竭发病中的神经内分泌细胞因子系统的研究.中国循环杂志,2001;16(4):243.
[14] Danser AH, Vankesteren CA, Bax WA, et al. Prorenin, venin, angiotensin and angiotensin—converting enzyme in normal and failing human hearts[J]. Circulation, 1997; 96(1): 220-226.
[15] Yoshimura M, Yasue H, Ogawa H. PathoPhysiological significance and clinical application of ANP and BNP in patients with heart failure[J]. Can J Physiol Pharmacol, 2001; 79: 730-735.
[16] 陶则伟,黄元伟.心衰学说的发展与防治.心血管病学进展,2003;24(1):67-70.
[17] Sutton M G J, Sharpe N. Left ventricular remodeling after myocardial infarction: pathophysiology and therapy[J]. Circulation, 2000; 101(22): 2981—2988.
[18] 陈齐红,覃数.肿瘤坏死因子—α和充血性心力衰竭.心血管病学进展,2004;25(2):89-91.
[19] Nicheretr J, Kemp M, Donrignez M, et al. Acute peripheral edetna in patients with chronic heart failure isessociate with endotoxemia and immune activation. J Am Coll Cardiol, 1998; 31: 155.
[20] Niebauer J, Colk HD, Kemp M, et al. Endotoxin and immune activation in chronic heart failure: a prospective cohort study. Lancet, 1999; 353: 1838-42.
[21] Mckinney W. Bacterial lipopolyoaccharide-atimulated releases of tumor necrosis factor-alpha from the isolated rat heart: the effect of aprotinin and forekolin[J]. Am Surg, 2003; 69: 131-135.
[22] Levine B, KaLman, Mayer L, et al. Elevated circulation levels of tumor necrosis factor in severe chronic heart failure[J]. N Engl J Med, 1990; 323(4): 236-241.
[23] 邱飞,王礼琛.肿瘤坏死因子α与心力衰竭的研究进展.国外医学药学分册,2003;30(6):326-330.
[24] Loppnow H, Westphal E, Buchhorn R, et al. Interleukin—1 and related protein in cardiovascular disease in adults and children. Shock, 2001; 16: 3—9.
[25] Torre—Amion G, Kapadia S, Benedict C, et al. Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: a report from the studies of left ventricular dysfunction(SOLVD)[J]. J Am Coll Cardiol, 1996; 27: 1202-1206.
[26] Berton C, Cordiano R. C-reactive Protein in acute myocardial infarction: association with heart failure [J]. Am Heart J, 2003; Jun, 145(6): 1094-101.
[27] Alonso-Martinez JL, Elorent-Diez B. C-reactive protein as predictor of improvement and readmission in heart failure[5]. Eur J Heart Fail, 2002; 4(3): 331-336.
[28] 励伟芬,柳茵,钟良.充血性心力衰竭患者血浆C反应蛋白水平变化及其意义.心脑血管病防治,2004;4(1):30-32.
[29] 尹芝兰,赵水平.充血性心力衰竭患者血清C-反应蛋白的变化及辛伐他汀的干预 作用.中国医师杂志,2003:5(9):1225-1226.
[30] 孙宁玲,李明.慢性充血性心力衰竭患者血浆中C-反应蛋白、肾上髓质素及内皮素水平变化的研究.中国循环杂志,2000;15(1):37-39.
[31] 金伟东,陶以嘉,潘宇红.纤维蛋白原,C-反应蛋白,白细胞计数与心功能不全的关系.中国临床医学,2001;8(3):259-260.
[32] Aukrust P, UelandT, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy[J]. AM J Cardiol, 1999; 83: 376-382.
[33] Takahashi N, Seko Y, Azuma M, et al. Evidence of cell-mediated cardiac myocyte injury involved in the heart failure of a patient with progressive systemic sclerosis[J]. Jpn Circ J, 1999; 63(1): 68-72.
[34] 陶志刚,于凌云,王洪敏.慢性充血性心力衰竭患者血清可溶性细胞问粘附分子-1的变化及与C-反应蛋白的相关性分析.中国心血管病研究杂志,2004,2(1):31-33.
[35] Lee RT, Lammerding J. Signaling pathways that influence extracellular remodeling. J Card Fail, 2002;8(6 Suppl):339-43.
[36] 陈晓锋,顾振纶,唐礼江.基质金属蛋白酶在心衰中作用的研究进展.中国药理学通报,2004;20(2):137-140.
[37] 杨志宏,郑兴.心室重构及心衰时基质金属蛋白酶的活性变化.国外医学·生理、病理科学与临床分册,2002;22(5):522-524.
[38] Doehner W, Rauchhaus M, Godsland IF, et al. Insulin resistance in moderate chronic heart failure is related to hyperleptinaemia, but not to norepinephrine or TNF—alpha. Int J Cardiol, 2002; 83(1): 73.
[39] 汪晓云,廖昆灵,卢微.瘦素、细胞因子与心功能不全关系的研究.贵州医药,2004;28(3):258-259.
[40] 张金国,杨娜,王学忠.充血性心力衰竭患者血浆瘦素水平的变化及其临床意义.济宁医学院学报,2003;26(4):4-6.
[41] 张子彬,Tsung O.Cheng[美],张玉传.充血性心力衰竭学.北京:科学技术文献出版社,2002年,第1版:223.
[42] The Task Force on Heart Failure of the European Society of Cardiology. Guideline for the diagnosis and treatment of chronic heart failure. Eur Heart J, 2000; 25:1527-1560.
[43] National Institute for Clinical Excellence. Chronic heart failure: management of chronic heart failure in adults in primary and secondary care. London: NICE, 2003.
[44] The Digitalis investigation Group. the effect of digoxin on mortality and morbidity in patients with heart failure[J]. New Eng J Med. 1997,336: 525-533.
[45] 袁进,唐镜波.地高辛治疗充血性心衰的研究进展及再评价.药物流行病学杂志,1998;7(3):135-139.
[46] Packer M, Cohn JN. Consensus recommendation for the management of chronic heart failure[J]. Am J Cardiol, 1999; 83,1A-38A.
[47] 林曙光,陈鲁原.心力衰竭治疗领域之用药进展.中国处方药,2004;22:26-28.
[48] Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus Elderly Study ELITE. Lancet, 1997; 349:747-752.
[49] Pitt B, Poole-Wilson PA, Segal R, et al. Effect of losartan compared with captopril on mortality in patients with heart failure: Randomized trial -The Losartan Heart failure Survival Study ELITE Ⅱ. Lancet, 2000; 355; 1582-1587.
[50] 中华医学会心血管学会.中华心血管病杂志编辑委员会.慢性收缩性心力衰竭治疗建议.中华心血管病杂志,2002;30:7-23.
[51] Philip A Poole-Wilson, Karl Swedberg, John G F Cleland, et al. Comparison of carvedilol and metoprolol on clinical outcomes in patients with chronic heart failure in the Carvedilol Or Metoprolol European Trial (COMET): randomised controlled trial. Lancet, 2003; 362: 7-13.
[52] Pitt B, Zannad F, Remme WJ, et al. Spirono lactone appears benificial regardles of ejection fraction: the RALES trial[J]. Circulation, 1999; 100(Suppl): 709-717.
[53] Ward MR, Kanellakis P, Ramsey D, et al. Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation, 2001;104(4), 467-472.
[54] John A, Joseph MD, Phil MS, et al. Expanding the outcomes in clinical trials of heart failure: The quality of life and economic components of EPHESUS (EPlerenone's neuroHormonal efficacy and survival study).Am Heart J, 2002; 143:636-42.
[55] 胡大一,马长生.心脏病学实践2002——规范化治疗,北京:人民卫生出版社,2002年,第1版:341.
[56] 李明龙.Nesiritide:一种有前途的治疗心力衰竭新药.医学综述,2004;10(1):24-26.
[57] Elkayam U, Silver MA, Burger AJ, et al. Effect of short—term therapy with nesiritide (B—type natriuretic peptide) or dobutamine on long term survival[J]. J Card Fail, 2000;6(1): 45.
[58] FarquharsonCA, Butler R, Hill A, et al. Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation, 2002;106(2): 221-6.
[59] 杨立宪,李桂平,钟思干,等.联合用小剂量甲状腺素治疗CHF对血清甲状腺素及心功能的影响.中华现代临床医学杂志,2003;6(1):494-495.
[60] 刘海宁,张兴华,耿庆信.老年慢性充血性心力衰竭患者甲状腺激素水平及小剂量甲状腺素治疗临床观察.中华老年医学杂志,2003;22(11):656-658.
[61] 王立志,孔祥泉,王英丽,等.小剂量甲状腺素长期治疗充血性心力衰竭的临床研究.中国综合临床,2003;19(11):987-988.
[62] Frishman WH. Recent advances in cardiovascular pharmacology[J]. Curr Prob Cardio, 2000; 25(4): 225.
[63] Milton P, Robert M, et al. Comparison of Omapatrilat and Enalapril in Patients With Chronic Heart Failure. Circulation, 2002; 106:920.
[64] 许项立,江荣炎.慢性心力衰竭的治疗进展.第六届岭南心血管病学术会议资料汇编,广州,2004年3月,116-118.
[65] Ruschitzka F, Moehrlen U, Quaschning T, et al. Tissue endothelin-converting enzyme activity correlates with cardiovascular risk factors in coronary artery disease[J].Circulation, 2000; 102(10): 1086-1092.
[66] 吴沃栋.心力衰竭生物学治疗的研究进展.广东医学,2004;25(3):343-344.
[67] Toussaint JF, Lavergne T, Olitrant J, et al. Biventricular pacing in severe heart failure patients reverses electromechanical dysynchronization from apex to base[J].PACE, 2000; 23: 1731-1734.
[68] Auricchio A, Stellbrink C, Sack S. The pacing therapies for congestive heart failure(PATH—CHF)study: rational, design and endpoints of a prospective randomized study[J]. Am J Cardial, 1999; 83: 130-135.
[69] Linde C, Leclercq C, Rex S, et al. Long-term benefits of biventricular pacing in congestive heart failure: result from the multisided Stimulation in Cardiomyopathy (MUSTIC) study [J]. J Am Coll Cardiol, 2002;40(1): 111-118.
[70] Abraham WT, Fisher WG, Smith AL, et al. Cardiac resynchronization in chronic heart failure[J].N Engl J Med, 2002; 346: 1845-1853.
[71] 张子彬.充血性心力衰竭,北京:科学技术文献出版社,1997,第2版:576.
[72] 郭毅.试论心衰及其治疗体会.四川中医,1996;14(8):6.
[73] 曹贵民.中医对心力衰竭的认识和治疗.陕西中医学院学报,1997;20(3):6.
[74] 陈可冀.心脑血管疾病研究(M),上海:科学技术出版社,1988年,第1版:24.
[75] 张志勇,王桂平.益气活血汤治疗缺血性心肌病心力衰竭65例观察.北京中医 2000;19(2):39.
[76] 刘宗莲,徐淑文,陈鼎棋.治疗心力衰竭经验.中医杂志,2000;41(4):204.
[77] 曹雪滨,浦斌红,胡元会,等.充血性心力衰竭的中医辨证分型特点.甘肃中医学院学报,1999;16(3):13.
[78] 周仲瑛,金妙文,吴勉华,等.益阴助阳、活血通脉法治疗充血性心力衰竭的临床研究.南京中医药大学学报,2000;11(1):13-15.
[79] 毛春燕.中医对充血性心力衰竭的认识及治疗对策.河北中医,2002;24(11):823.
[80] 吴勉华.充血性心力衰竭中医病机探讨.南京中医药大学学报,2001;17(4):206.
[81] 蔡辉,胡婉英.中医药治疗充血性心力衰竭的理论研究概况.河北中医药学报,2000;15(3):41-43.
[82] 杜惠芳,杨加禄,郭素英.慢性心衰与痰之关系初探.河南中医药学刊,1998;9(3):34-36.
[83] 冯国标.略论慢性心衰的辨证论治.河南中医药学刊,1998;13(2):6-7.
[84] 杨培君,杨磊.充血性心力衰竭的中医证治概要.陕西中医学院学报,2002;25(1):2.
[85] 谢乐.中医分型治疗充血性心力衰竭77例.四川中医,2002;20(6):41.
[86] 王素琴.心衰的中医辨证施治.河北医学,2002;8(3):283-284.
[87] 马术明.慢性充血性心力衰竭的辨证论治.吉林中医药,2004;24(2):6-8.
[88] 郑友祥,黄平,夏建华.中西医结合疗法治疗慢性充血性心力衰竭84例.现代中西医结合杂志,2004;13(5):590-591.
[89] 吕凯.健脾利水法治疗慢性心衰38例.中医研究,2002;15(2):28-29.
[90] 谭旭宏.健脾法与小剂量肝素合用在顽固性心力衰竭中的应用初探.贵阳中医学院学报,2004;26(1):29-30.
[91] 张振琪.益气活血法治疗慢性心力衰竭30例临床观察.中国医药学报,2003;18(11):702.
[92] 郭志华,毛以林,石青,等.益气活血利水法治疗慢性心力衰竭的临床研究.中华实用中西医杂志,2004;4(3):318-319.
[93] 鲁桂芬.益气温阳利水法治疗充血性心力衰竭58例.河北中医,2004;26(2):99-100.
[94] 孙长春,顾月星,王一新,等.补阳还五胶囊治疗无症状性心力衰竭48例临床观察.江苏中医药,2003;24(12):16-17.
[95] 林萍.不长稳心颗粒对老年冠心病充血性心力衰竭患者校正QT离散度的影响.中华中西医学杂志,2004;2(1):60-61.
[96] 陈志强,洪涛,赖颢,等.参附注射液治疗二尖瓣替换术后心功能不全的临床观察.中国中医急症,2003;12(6):531,561.
[97] 王燕.参附注射液治疗心功能不全疗效观察.中华中西医杂志,2003: 4(10):1533-1534.
[98] 季文.参附注射液治疗肺源性心脏病心力衰竭的临床观察.山西医药杂志,2004;33(1):79-80.
[99] 胡元会,曹雪滨,曹贵民.中药心复康治疗气虚血瘀型充血性心力衰竭33例疗效观察.浙江中医学院学报,2002;24(2):39.
[100] 吴勉华.养心通脉合剂治疗充血性心力衰竭临床研究.山东中医杂志,2001;20(12):715.
[101] 卢健棋.参麦注射液治疗充血性心力衰竭的研究概况.中西医结合心脑血管病杂志,2003;1(10):600-601.
[102] 黄然.参麦注射液辅助治疗心力衰竭52例疗效观察.中华新医学,2004;5(2):103-104.
[103] 龙明智,王迪斌,杨季明,等.参麦注射液治疗充血性心力衰竭的临床观察.中国中西医结合杂志,2003;23(11):808-810.
[104] 陈海燕,吴焕林.参麦注射液治疗慢性充血性心力衰竭的疗效观察.现代中西医结合杂志,2004;13(1):30-31.
[105] 杨茂平,刘兴邦.生脉注射液辅助治疗难治性心力衰竭22例临床观察.中华现代中西医杂志,2003;1(5):418.
[106] 汤应宗.生脉注射液治疗顽固性心衰32例临床观察.中华医药学杂志,2003;2(10):88-89.
[107] 杨瑞华,张瑞海,孙亚利.生脉注射液治疗充血性心力衰竭30例.中国民间疗法,2004;12(1):45-46.
[108] 姜淑琴.生脉注射液治疗充血性心力衰竭的疗效观察.中华综合医学杂志,2004;6(3):64-65.
[109] 谭辉,宋开兰,刘娅.大黄对重度充血性心力衰竭患者细胞因子及氧化应激的影响.中国现代医学杂志,2003;13(22):99-100,102.
[110] 姜寅光,李隽.益母草化血中之水治慢性左心衰竭.中医杂志,2003:44(12):891.
[111] 杨孟考.单味葶苈子治疗顽固性心衰23例.中国社区医师,2002;18(20):40.
[112] 郭卫宾.灯盏花注射液治疗肺心病心衰56例疗效观察.医学文选,2003;22(6):901.
[113] 杜秀玉.红花注射液治疗肺心病顽固性心力衰竭的疗效观察.中国中西医结合杂志,2003;23(5):393.
[114] 梁春才.黄芪治疗难治性心衰近况.辽宁中医杂志,2001;28(9):575-576.
[115] 尹乐安.黄芪注射液对肺心病心力衰竭心功能的影响(附102例报告).中国医师杂志,2004;6(3):427.
[116] 刘永新.黄芪注射液联用心先安治疗肺心病心衰50例疗效分析.中国全科医 学,2003;6(11):917.
[117] 刘志高,熊正明,余细勇.黄芪注射液对充血性心力衰竭患者免疫功能的影响.中国中西医结合杂志,2003;23(5):351-353.
[118] 翟世民.黄芪注射液辅助治疗顽固性心力衰竭的疗效观察.中国社区医师,2004;(3):33.
[119] 赵海洋,孙西武.黄芪注射液联合欣康注射液治疗心力衰竭54例临床观察.中华医学研究杂志,2003;3(5):455.
[120] 钱海凌,黄立武.大剂量黄芪注射液治疗难治性心衰的临床观察.辽宁中医杂志,2000;27(5):202-203.
[121] 唐志新,李毅夫,洪新枝,等.黄芪治疗心力衰竭及其对肿瘤坏死因子的影响.中国药房,2001;12(2):917.
[122] 邓铁涛.邓铁涛临床经验辑要,北京:中国医药科技出版社,1998年,第1版:22.
[123] 郑筱萸.中药新药临床研究指导原则(试行),北京:中国医药科技出版社,2002年,第1版:77.
[124] 郑筱萸.中药新药临床研究指导原则(试行),北京:中国医药科技出版社,2002年,第1版:378.
[125] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版:383.
[126] 邓铁涛.邓铁涛医集,北京:人民卫生出版社,1995年,第1版.
[127] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版:81.
[128] 刘宏伟,付红莉.6分钟步行试验对慢性心衰患者心功能的评估.国外医学.心血管疾病分册,2001;28(2):87-88.
[129] 郑筱萸.中药新药临床研究指导原则(试行).北京:中国医药科技出版社,2002年,第1版.
[130] 中华医学会心血管病学会,中华心血管病杂志编辑委员会.慢性收缩性心力衰竭治疗建议.中华心血管病杂志,2002年;30(1):7-21.
[131] Bittner V, Weiner DH, Yuauf S, et al. Prediction of niortality and morbidity with a 6-minute walk test in patients with left ventricular dysfunction [J], JAMA, 1993; 270(14): 1702-1707.
[132] 阎伟,余静.六分钟步行试验:评估慢性心衰患者心功能的一种简单客观方法.心血管病学进展.2002;23(2):86-88.
[133] Cohn JN. Structural change incardiovascular disease. Am Cardiol, 1995; 76:34.
[134] Tmughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure